

Ethiopia support for Pentavalent vaccine

This decision letter sets out the programme terms of a programme.

1.	Country: Ethiopia	
2.	Grant number: 16-ETH-04a-X	
3.	Date of decision letter: 19 November 2015	
1	Date of the partnership framework agreement: 23 July 2013	

- 4. Date of the partnership framework agreement: 23 July 2013
- 5. Programme title: New vaccine support (NVS), Pentavalent Routine
- 6. Vaccine type: Pentavalent
- 7. Requested product presentation and formulation of vaccine: DTP-HepB-Hib, 1 dose per vial, LIQUID
- 8. Programme duration¹: 2007 2016
- **9. Programme budget (indicative):** (subject to the terms of the partnership framework agreement)

	2007-2015	2016	Total ²
Programme budget	US\$ 213,484,511 ³	US\$ 12,569,500	US\$ 226,054,011

- 10. Vaccine introduction grant: Not applicable
- **11. Indicative annual amounts:** (subject to the terms of the partnership framework agreement)⁴

Type of supplies to be purchased with	2007-2015	2016
Gavi funds in each year	y .	
Number of Pentavalent vaccines doses		6,629,600
Number of AD syringes		7,714,900
Number of safety boxes		84,875
Annual amounts	US\$ 213,484,511 ⁵	US\$ 12,569,500

- **12. Procurement agency:** UNICEF. The Country shall release its co-financing payments each year to UNICEF.
- 13. Self-procurement: Not applicable

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the consolidated amount for all previous years.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years.



14. Co-financing obligations: Reference code: 16-ETH-04a-X-C

According to the co-financing policy, the Country falls within the group Initial self-financing.

The following table summarises the co-financing payments and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased	2016
with Country funds in each year	
Number of vaccine doses	810,200
Value of vaccine doses	US\$1,455,930
Total co-financing payments	US\$1,488,000
(including freight)	

- 15. Operational support for campaigns: Not applicable
- **16. Additional reporting requirements:** The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts.

Reports and other information	Due dates
To prepare for the annual procurement of vaccines,	15 May 2016
Country shall submit the following information in May	
each year: number of children to be vaccinated,	
vaccine stock levels including buffer stock, wastage	
rates, any proposed changes in presentation or	
minimum co-financing levels and vaccines received.	
In accordance with applicable Gavi processes,	To be agreed
Country shall report on programmatic and financial	with Secretariat
performance.	

- 17. Financial clarifications: Not applicable
- 18. Other conditions: The country is reminded of its obligations under the PFA in respect of insurance and is requested to provide information to Gavi on the steps it has taken in this regard.

Signed by,

On behalf of Gavi Hind Khatib-Othman

Managing Director, Country Programmes

dilant . Ho bi

19 November 2015



Ethiopia support for Pneumococcal vaccine

This decision letter sets out the programme terms of a programme.

1.	Country: Ethiopia
2.	Grant number: 1517-ETH-12b-X
-	5 / 6 / 1 / 1 / 1 / 1 / 1 / 1 / 1 / 1 / 1

- 3. Date of decision letter: 19 November 2015
- 4. Date of the partnership framework agreement: 23 July 2013
- 5. Programme title: New vaccine support (NVS), Pneumococcal Routine
- 6. Vaccine type: Pneumococcal
- **7.** Requested product presentation and formulation of vaccine: Pneumococcal (PCV10), 2 doses per vial, LIQUID
- 8. Programme duration⁶: 2011 2017
- **9. Programme budget (indicative):** (subject to the terms of the partnership framework agreement)

	2011-2015	2016	2017	Total ⁷
Programme budget (US\$)	228,376,6838	40,445,000	33,953,000	302,774,683

- 10. Vaccine introduction grant: Not applicable
- **11. Indicative annual amounts:** (subject to the terms of the partnership framework agreement)⁹

Type of supplies to be purchased with	2011-2015	2016
Gavi funds in each year		
Number of Pneumococcal vaccines doses		8,364,400
Number of AD syringes		8,767,900
Number of safety boxes		96,450
Annual amounts	US\$228,376,683 ¹⁰	US\$40,445,000

- **12. Procurement agency:** UNICEF. The Country shall release its co-financing payments each year to UNICEF.
- 13. Self-procurement: Not applicable

⁶ This is the entire duration of the programme.

⁷ This is the total amount endorsed by Gavi for the entire duration of the programme.

⁸ This is the consolidated amount for all previous years.

⁹ This is the amount that Gavi has approved.

¹⁰ This is the consolidated amount for all previously approved years.



14. Co-financing obligations: Reference code: 1517-ETH-12b-X-C

According to the co-financing policy, the Country falls within the group Initial self-financing.

The following table summarises the co-financing payments and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased	2016
with Country funds in each year	
Number of vaccine doses	522,400
Value of vaccine doses	US\$ 1,761,507
Total co-financing payments	US\$ 1,777,500
(including freight)	

- 15. Operational support for campaigns: Not applicable
- **16. Additional reporting requirements:** The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts.

Reports and other information	Due dates
To prepare for the annual procurement of vaccines,	15 May 2016
Country shall submit the following information in May	
each year: number of children to be vaccinated,	
vaccine stock levels including buffer stock, wastage	
rates, any proposed changes in presentation or	
minimum co-financing levels and vaccines received.	
In accordance with applicable Gavi processes,	To be agreed
Country shall report on programmatic and financial	with Secretariat
performance.	

- 17. Financial clarifications: Not applicable
- 18. Other conditions: Not applicable

Signed by,

On behalf of Gavi Hind Khatib-Othman

Managing Director, Country Programmes

19 November 2015